Kyverna CMO James Chung resigns; receives $220K severance and COBRA

Kyverna Therapeutics, Inc.

CMO James Chung's employment terminated effective November 22, 2024.
Severance of $220,000 (6 months base salary) plus COBRA premiums for up to 6 months.
Stock options cease vesting as of Separation Date; release of claims signed.
No replacement named; Company expresses best wishes in future endeavors.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Chung

Chief Medical Officer

KYTX · Kyverna Therapeutics, Inc.

Effective: 2024-11-22
Filed: November 26, 2024, 6:59 PM ET

As previously disclosed, James Chung, M.D., Ph.D., Chief Medical Officer of Kyverna Therapeutics, Inc. (the “Company”), resigned from the Company, to be effective as of November 22, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

James Chung resigned as Chief Medical Officer at Kyverna Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

As previously disclosed, James Chung, M.D., Ph.D., Chief Medical Officer of Kyverna Therapeutics, Inc. (the “Company”), resigned from the Company, to be effective as of November 22, 2024.

View on SEC.gov

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-131074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.